» Articles » PMID: 33293629

EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood

Abstract

In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.

Citing Articles

A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.

Buzatu I, Tataranu L, Duta C, Stoian I, Alexandru O, Dricu A Int J Mol Sci. 2025; 26(5).

PMID: 40076810 PMC: 11899917. DOI: 10.3390/ijms26052192.


Nanotherapy of Glioblastoma-Where Hope Grows.

Grzegorzewski J, Michalak M, Woloszczuk M, Bulicz M, Majchrzak-Celinska A Int J Mol Sci. 2025; 26(5).

PMID: 40076445 PMC: 11898975. DOI: 10.3390/ijms26051814.


Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.

Vivancos Sanchez C, Esteban Rodriguez M, Pelaez Garcia A, Taravilla-Loma M, Rodriguez-Dominguez V, Rodriguez-Antolin C Cancers (Basel). 2025; 17(5).

PMID: 40075591 PMC: 11898826. DOI: 10.3390/cancers17050744.


Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.

Neth B, Kraft R, Eschbacher K, Johnson D, Decker P, Sener U J Neurooncol. 2025; .

PMID: 40048040 DOI: 10.1007/s11060-025-04994-2.


Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME).

Dasgupta A, Sawant S, Chatterjee A, Gota V, Sahu A, Choudhari A Cancer Med. 2025; 14(5):e70657.

PMID: 40025673 PMC: 11872794. DOI: 10.1002/cam4.70657.


References
1.
Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F . Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016; 18(11):1529-1537. PMC: 5063521. DOI: 10.1093/neuonc/now133. View

2.
Batchelor T, Duda D, Tomaso E, Ancukiewicz M, Plotkin S, Gerstner E . Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28(17):2817-23. PMC: 2903316. DOI: 10.1200/JCO.2009.26.3988. View

3.
Wahl M, Phillips J, Molinaro A, Lin Y, Perry A, Haas-Kogan D . Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2016; 19(2):242-251. PMC: 5464133. DOI: 10.1093/neuonc/now176. View

4.
Press R, Shafer S, Jiang R, Buchwald Z, Abugideiri M, Tian S . Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. Cancer. 2020; 126(14):3255-3264. DOI: 10.1002/cncr.32797. View

5.
Peeters M, Dirven L, Koekkoek J, Gortmaker E, Fritz L, Vos M . Prediagnostic symptoms and signs of adult glioma: the patients' view. J Neurooncol. 2020; 146(2):293-301. DOI: 10.1007/s11060-019-03373-y. View